Compare DexCom, Inc. (DXCM) vs iShares 3 7 Year Treasury Bond ETF (IEI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs iShares 3 7 Year Treasury Bond ETF — how do they compare? DexCom, Inc. trades at $90.63 (market cap $33.79B), while iShares 3 7 Year Treasury Bond ETF trades at $116.45. The key difference: DexCom, Inc. is trading nearer its 52-week high, iShares 3 7 Year Treasury Bond ETF nearer its low. Which is the better fit depends on your goals.
| DXCM | IEI | |
|---|---|---|
Market Cap | $33.79B | — |
Sector | Health | Fixed Income |
52-Week High | $89.53 | $120.72 |
52-Week Low | $54.84 | $116.16 |
Enterprise Value | $33.24B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $91.00, up 3.82% today and near its 52-week high, with bullish technical signals from moving averages and strong fundamentals. Recent Q2 2026 earnings beat expectations with EPS of $0.70 versus $0.61 expected, driven by 13% revenue growth and margin expansion. The company raised full-year 2026 guidance, reflecting robust demand for continuous glucose monitors.
The outlook is positive due to sustained revenue growth, profitability improvements, and analyst consensus favoring buys. Risks include competitive pressures and potential regulatory scrutiny, but institutional ownership trends and earnings momentum support a constructive view for investors seeking exposure to medical technology.
IEI, the iShares 3-7 Year Treasury Bond ETF, trades at $116.46, up 0.18% today, with a bearish technical signal from moving averages and neutral oscillators. The ETF has paid recent dividends, including $0.38 per share in July 2026. News highlights focus on Treasury yield volatility amid inflation data and geopolitical tensions, influencing bond market sentiment.
Outlook is cautious due to bearish technicals and rising yield pressures. Opportunities include government backing and income from dividends, but risks involve Fed rate hike expectations and oil-driven inflation. Investors face volatility from macroeconomic shifts and bond market reactions to policy changes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About iShares 3 7 Year Treasury Bond ETF
IEI tracks the ICE U.S. Treasury 3-7 Year Bond Index, offering exposure to intermediate-term government debt. It serves as a conservative middle ground in the Treasury yield curve, providing higher yields than short-term bills with less volatility than long-term bonds.
Read more on IEI →
